Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to Know: Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to Know

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron.

Mark Lebwohl, MD

Faculty

Dean for Clinical Therapeutics
Waldman Professor and Chairman
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Recognize the clinical features of Atopic Dermatitis (AD) to improve the diagnosis of children and adults with moderate-to-severe AD
Apply recommendations from the AAD guidelines for the diagnosis, management, and long-term treatment of patients with AD
Integrate available therapies to tailor treatment plans for patients with AD
Educate patients and caregivers to improve outcomes of patients with AD through shared-decision making

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONFLICTS OF INTEREST/DISCLOSURES

Mark Lebwohl, MD

Consultant: Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, Boehringer-Ingelheim, Bristol-Myers Squibb, Cora therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO, meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/ Dr. Reddy’s abs, Theravance, Verricca

Grant/Research Support: Abbvie, Amgen, Arcutis, AstraZeneca, Boehringer Ingelheim, Celgene, Clinuvel, Eli Lilly, Incyte, Janssen Research & Development, Kadmon Corp., LEO, Medimmune, Novartis, Ortho Dermatologics, Pfizer, Sciderm UCB, ViDac

[fc+360]

Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to Know: Online CME Activity

Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to KnowThis CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.This activity is supported by an educational grant from Sanofi Genzyme and Regeneron.

Mark Lebwohl, MD

CONFLICTS OF INTEREST/DISCLOSURES

Long-Term Management of Moderate-to-Severe Atopic Dermatitis: What You Really Need to Know

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron.